A Randomized, Double-Blind, Placebo Controlled Vaccination-Challenge Study of ACE393 to Determine Efficacy Against the Symptoms of Moderate to Severe Campylobacter Jejuni Infection in Normal Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2015
At a glance
- Drugs ACE 393 (Primary)
- Indications Campylobacter infections; Traveller's diarrhoea
- Focus Therapeutic Use
- Sponsors ACE BioSciences
- 11 Mar 2009 Planned number of patients changed from 60 to 72; trial IDs, centres, investigators, sponsors, start and end dates reported by ClinicalTrials.gov.
- 10 Mar 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 10 Mar 2009 New source identified and integrated (ClinicalTrials.gov).